Back to search

Boston University

The influence of UBE3A, NEDD4L, and ARFGEF2 on the progression of Angelman syndrome and sickle cell anemia

Abstract

dc:description.abstract

This project investigates the impact of UBE3A, NEDD4L, and ARFGEF2 on disorder and disease in humans. UBE3A is a member of the homologous to E6AP COOH-terminus (HECT) E3 ubiquitin ligase family and is parentally imprinted in certain cell types. Mutation of the gene causes Angelman syndrome (AS), which is characterized by developmental delays, mental retardation, motor ataxia, and seizures. Patients frequently display excitable behavior, laughing, and a happy appearance. I found a previously unreported UBE3A candidate mutation, F606S, in twin boys diagnosed with AS.To test the change's clinical significance, I looked at its presence throughout the probands' family by sequencing, its influence on expression levels by qRT-PCR, and structure change predictions. The S606 is located in the functional domain of the enzyme, and its inheritance pattern correlates with disorder expression. The expression data is inconclusive, however, which highlights problems of using human experimental subjects. Nevertheless, there are indications that the F606S missense change could be responsible for AS. Another HECT E3 ligase, NEDD4L influences hypertension severity. Hypertension and inflammation are a complication of sickle cell anemia (SCA) and can affect patient outcome. Mutations in the gene increase epithelial Na+ channel surface expression and thus raise sodium uptake in epithelial cells. It is possible NEDD4L is a component of hypertension in a system instrumental to SCA development, endothelial cells. I conducted a pilot study to determine the effectiveness of NEDD4L knockdown by siRNA as a model for gene dysfunction and found that expression levels were significantly reduced in human pulmonary artery endothelial cells (HPAEC). I also did a preliminary study of the knockdown's influence on other genes that showed no change in ACTB, ARFGEF2, NOS3, or TNFRSFJA expression. Inflammation is a key component in hypertension. ARFGEF2 is a gene that could modulate endothelial inflammation response in sickle cell anemia. It is a GDP-GTP exchange factor involved in the downregulation of the TNF-α receptor, TNFRSF IA, a significant part of the inflammatory signaling pathway. Data from a gene chip expression assay yielded genes with four-fold expression change after ARFGEF2 knockdown. There is a strong inflammatory trend in the functional connections between these genes. It is a promising indication that ARFGEF2 has a role in inflammation, especially in immune response and intercellular signaling.

Degree

thesis:*
Name thesis:degree_name
Master of Arts
Level thesis:degree_level
masters
Discipline thesis:degree_discipline
Biochemistry
Grantor dc:publisher
Boston University
Year dc:date.issued
2012

Author and committee

dc:creator, dc:contributor.*
Author dc:creator
  • Wu, Katie Jennifer

Rights

Language dc:language.iso
en_US

Identifiers

dc:identifier.*
Dc Identifier Other
(ALMA)contemp

Chain of custody

source
Harvested from
Boston University
Base URL
open.bu.edu/oai/request
Last updated
2026-11-18
Source record
OAI-PMH GetRecord
related terms
citation

Wu, Katie Jennifer. The influence of UBE3A, NEDD4L, and ARFGEF2 on the progression of Angelman syndrome and sickle cell anemia. masters thesis, Boston University, 2012. https://hdl.handle.net/2144/12683